Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Heron Therapeutics (HRTX) over the last 14 years, with Q3 2025 value amounting to $55.5 million.

  • Heron Therapeutics' Cash & Current Investments fell 2172.8% to $55.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.5 million, marking a year-over-year decrease of 2172.8%. This contributed to the annual value of $59.3 million for FY2024, which is 2627.32% down from last year.
  • As of Q3 2025, Heron Therapeutics' Cash & Current Investments stood at $55.5 million, which was down 2172.8% from $40.6 million recorded in Q2 2025.
  • Heron Therapeutics' 5-year Cash & Current Investments high stood at $257.7 million for Q2 2021, and its period low was $33.2 million during Q2 2023.
  • In the last 5 years, Heron Therapeutics' Cash & Current Investments had a median value of $77.4 million in 2023 and averaged $97.6 million.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first crashed by 6758.05% in 2022, then skyrocketed by 10258.39% in 2024.
  • Heron Therapeutics' Cash & Current Investments (Quarter) stood at $157.6 million in 2021, then crashed by 46.15% to $84.9 million in 2022, then dropped by 5.24% to $80.4 million in 2023, then fell by 26.27% to $59.3 million in 2024, then fell by 6.4% to $55.5 million in 2025.
  • Its Cash & Current Investments stands at $55.5 million for Q3 2025, versus $40.6 million for Q2 2025 and $50.7 million for Q1 2025.